{
  "created_at": "Fri Jun 18 6:32:2 +0000 2021",
  "id_str": "1405759730014822400",
  "full_text": "Brain-cancer drug Gleostine is no longer covered by Medicare Part D, leaving some patients struggling to cover full cost, which can run over $1,000 per pill https://t.co/2cpQTJIlgF",
  "display_text_range": [
    0,
    180
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/2cpQTJIlgF",
        "expanded_url": "https://on.wsj.com/3vwqVpP",
        "display_url": "on.wsj.com/3vwqVpP",
        "indices": [
          157,
          180
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 51,
  "favorite_count": 84,
  "possibly_sensitive": false,
  "original_created_at": "Fri Jun 18 05:30:12 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "脳腫瘍治療薬GleostineはメディケアパートDの対象外となり、患者の中には1錠あたり1,000ドル以上の費用を負担しなければならない人もいます。https://t.co/2cpQTJIlgF"
    },
    {
      "locale": "zh",
      "full_text": "脑癌药物Gleostine不再由Medicare D部分承保，使一些患者难以支付全部费用，每片药的费用可能超过1000美元 https://t.co/2cpQTJIlgF"
    },
    {
      "locale": "zh-Hant",
      "full_text": "腦癌藥物Gleostine不再由Medicare D部分承保，使一些患者難以支付全部費用，每片藥的費用可能超過1000美元 https://t.co/2cpQTJIlgF"
    }
  ]
}